Treatment of Apomorphine-induced Skin Reactions: a Pilot Study

Inclusion Criteria: * Female and male subjects aged ≥30; * Diagnosis of idiopathic Parkinson's disease of \>3 years' duration, defined by the United Kingdom (UK) Brain Bank criteria, with the exception of \>1 affected relative being allowed, without any other known or suspected cause of Parkinsonism (Gibb \& Lees, 1988); * Treatment with continuous subcutaneous apomorphine infusion; * Having apomorphine-induced skin reactions (i.e. erythema, swelling and/or nodule formation); * Male and female patients must be compliant with a highly effective contraceptive method (oral hormonal contraception alone is not considered highly effective and must be used in combination with a barrier method) during the study, if sexually active; * Subjects considered reliable and capable of adhering to the protocol, visit schedule, and medication intake according to the judgement of the investigator. Exclusion Criteria: * High suspicion of other parkinsonian syndromes; * History of respiratory depression; * Hypersensitivity to hydrocortisone or any excipients of the medicinal product; * Concomitant therapy with histamine antagonist; * Known with Cushing's disease or hypercortisolism * Any medical condition that is likely to interfere with an adequate participation in the study including e.g. current diagnosis of unstable epilepsy; clinically relevant cardiac dysfunction and/or myocardial infarction or stroke within the last 12 months; * Pregnant and breastfeeding women; * Current infectious disease with fever at the time of investigation.